Organisation paid for research Program year 2025 Source: CMS Open Payments

Pinnacle Clinical Research PLLC

Neither a doctor nor a teaching hospital

Research payments

$7,931,067

791 payments

Through program year 2025, Pinnacle Clinical Research PLLC is reported as receiving $7,931,067 in research payments, across 791 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,547,829 310
2024 Research $816,840 126
2023 Research $1,277,458 62
2022 Research $1,636,031 73
2021 Research $889,479 61
2020 Research $221,076 41
2019 Research $1,542,354 118

Breakdown

Who paid Research payments · program years 2019–2025
  1. Madrigal Pharmaceuticals $2,312,204 417 payments
  2. Genentech, Inc. $1,738,954 119 payments
  3. Gilead Sciences, Inc. $1,486,562 109 payments
  4. Eli Lilly and Company $905,723 32 payments
  5. Intercept Pharmaceuticals, Inc. $525,823 67 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $432,157 1 payment
  7. Pfizer Inc. $163,950 21 payments
  8. Amgen Inc. $162,092 1 payment
  9. Provepharm Inc. $145,030 2 payments
  10. Allergan Inc. $30,146 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase II Antifgfr 1 in Nash $1,049,352 82 payments
  2. A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $989,516 152 payments
  3. A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis to Resolve Nash and Reduce Progression to Cirrhosis Andor Hepatic Decompensation $872,010 217 payments
  4. A 52Week Phase 3 Openlabel Extension Study With A Doubleblind Leadin to Evaluate Safety and Biomarkers of Resmetirom Mgl3196 in Patients With Nonalcoholic Fatty Liver Disease Nafld Maestronafldopenlabelextension Maestronafldole $450,678 48 payments
  5. POCC in NASH $432,157 1 payment
  6. A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Ly3849891 in Participants With Nonalcoholic Fatty Liver Disease Who Have the Pnpla3 I148m Genotype $410,460 2 payments
  7. Giredestrant HI $408,703 25 payments
  8. 1011866 $282,394 22 payments
  9. Pralsetinib Hepatic Impairment Study $280,899 12 payments
  10. Prescreening Study for Patients With Nonalcoholic Fatty Liver Disease (Nafld) Who Are Carriers of the Pnpla3 I148m Allele $211,718 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record